575 results about "Antithrombotic" patented technology

A catheter including a main body having a first end, a second end, a lumen extending between the first end and the second end, a first section located proximal the first end of the main body and second section located proximal the second end of the main body. An inhibitory polymer is disposed at the first section. The inhibitory polymer includes one or more members selected from the group consisting of antiproliferatives, antithrombotics, thrombolytics, and fibrinolytics. An antimicrobial agent is disposed at the second section. The main body has a length such that when the catheter is at least partially implanted the first end accesses a body vessel and at least a portion of the second section is disposed within a subcutaneous space of a patient.

A vascular or endoluminal stent is adapted to be implanted in a vessel, duct or tract of a human body to maintain an open lumen at the site of the implant. The sidewall of the open-ended tubular structure of the stent is a base layer of a metal biologically compatible with blood and tissue of the human body. An intermediate metal particle layer of substantial greater radiopacity overlies the base layer, with particles bonded to the base layer and to each other to leave interstices therebetween as a repository for retaining and dispensing drugs or other agents for time release therefrom after the stent is implanted, to assist the stent in maintaining the lumen open. The particles are composed primarily of a noble metal—an alloy of platinum-iridium. The sidewall has holes extending therethrough, and the particle layer resides along the outward facing and inward facing surfaces, and the edges of the through holes and open ends of the sidewall. The larger particles are bonded to surfaces of the sidewall and progressively smaller particles are bonded to those and to each other up to the outer portion of the particle layer. Exposed surfaces of the particle layer are coated with ceramic-like iridium oxide or titanium nitrate, as a biocompatible material to inhibit irritation of tissue at the inner lining of the vessel when the stent is implanted. One or more anti-thrombotic, anti-platelet, anti-inflammatory and/or anti-proliferative drugs are retained in the interstices, together with a biodegradable carrier for time release therefrom. In an alternative embodiment, the intermediate layer is solid and the biodegradable carrier and drugs or agents therein are applied to the surface of the ceramic-like coating. Gene transfer is alternatively used to control tissue proliferation.

The present invention relates to the synthesis of beta-tetrahydro carboline carboxylic acid and its nanoparticle preparation; liquid phase process of gradually grafting peptide to obtain protected tetrapeptide intermediate, which, after eliminating its Boc, is condensated with N-Boc-beta-tetrahydro carboline carboxylic acid and further HF treated to eliminate its protection to obtain the said compound; the nanoparticle of tetrahydro carboline carboxylic acid and the in-vitro and in-vivo activity of said compound in-vitro and in-vivo experiments show that the compound of the present invention has excellent activity of resisting blood platelet aggregation, effect of resisting cell adhesion and effect of resisting thrombus.

The invention discloses a halogen substituted 2-(a-hydroxyl amyl) benzoate compound, a preparation method and medicinal application thereof, which belong to the technical field of organic chemical synthesis. The structural formula of the compound which is showed as above has an antimer structure, wherein <R1> represents a halogen atom; n is equal to 1 to 3; and M represents a univalent metallic ion or a bivalent metallic ion or a trivalent metallic ion or an organic base. The compound has the advantages of better activity on preventing and treating cardio-cerebral ischemia diseases, improving cardio-cerebral circulation disturbance and resisting thrombus, and the like.

Aiming at the conditions that heparin has severe bleeding side effects in clinical practice and clinical application thereof is restricted, the invention discloses a technique for producing ultra-low molecular heparin sodium (calcium). The technique comprises the following steps of: taking heparin sodium solution, adding sodium nitrite solution for cracking; adjusting the lysis buffer by using alkaline; absorbing impurities by using an anion-exchange column; washing for obtaining ultra-low molecular heparin calcium; carrying out filtration by using an ultrafiltration membrane and obtaining a precipitate by using alcohol; and after desalting, dehydration, re-precipitation, cooling and drying, obtaining a finished product of ultra-low molecular heparin calcium. The product has better and safer antithrombotic effect under low level of anticoagulation, and can be widely used for preventing and treating diseases such as deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, and the like.

The invention relates to implantable vascular access ports that can release agents such as antibiotics, anti-thrombogenics and anti-proliferatives. The invention also relates to ports having locking mechanisms that prevent accidental disengagement, and structures that facilitate surgical implantation and provide for long-term stability and use of the port.

Disclosed herein are methods for modifying a substrate having a hydrophobic surface. Also disclosed are modified hydrophobic substrates. The modified hydrophobic substrates and methods disclosed herein advantageously improve cell affinity and antithrombogenicity of hydrophobic surfaces.

The present invention relates to methods and compositions for identifying and treating subjects in need of antithrombotic therapies but who are not responsive to aspirin.

The present invention relates to certain new pyridin analogues of Formula (I)

to processes for preparing such compounds, to their utility as P2Y₁₂ inhibitors and as anti-thrombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.

The invention discloses a method for evaluating chemical composition of Rosa xanthina on the basis of antithrombotic spectrum-effect relationship. The method comprises the following steps: preparing extract of different polar components of the Rosa xanthina with a modern separation technology; establishing fingerprint of extract of each component with high-performance liquid chromatography, and calibrating characteristic peaks; evaluating antithrombotic activity of different extract on the basis of platelet aggregation inhibition rate, prothrombin time, thrombin time and activated partial thromboplastin time as indexes; substituting fingerprint characteristic peak data and pharmacodynamical activity data into a mathematical model for spectrum-effect correlation analysis, and evaluating pharmacodynamical activity of the characteristic peaks. With adoption of the method for evaluating the chemical composition of the Rosa xanthina on the basis of the antithrombotic spectrum-effect relationship, the antithrombotic chemical composition in the Rosa xanthina can be evaluated rapidly and accurately, a scientific and effective method is provided for research of pharmacodynamic material basis and quality control of the Rosa xanthina, and reference is provided for further development of Rosa xanthina drugs or health care products for treating thrombotic diseases.

The invention discloses a processing technique of health thorn tea and processing equipment for health thorn tea, which relate to the technical field of processing of agricultural products. The health thorn tea is made of fresh thorn tea leaves. The processing technique includes cutting, primary fixation, primary spreading and cooling, secondary fixation, secondary spreading and cooling, primary rolling, tertiary spreading and cooling, primary baking, secondary rolling, fourth spreading and cooling, secondary baking, grading and packaging. The processed health thorn tea has the advantages of blood glucose lowering, blood lipid lowering, blood pressure lowering, immunity enhancement, heart rate slowing, coronary flow increasing, anticoagulation, antithrombosis, hypoxia tolerance, mononuclear macrophage functional promotion, radio resistance and the like, and is suitable for middle-aged and aged people and people with hyperlipidemia, hypertension and hyperglycemia. The processing technique and the processing equipment for the health thorn tea can also be used for processing common tea and other types of health tea.

The invention relates to a bioengineering technology, in particular to a small-caliber biotic artificial blood vessel with anti-thrombus formation and anti-intimal hyperplasia functions. Firstly, the key technology of accellular materials and natural polymer composition is used, and through multiple modes, neurotrophic factors are effectively coupled as functional modules to perform modification on blood vessel supports. Furthermore, through the strategy of constructing in body, the small-caliber engineering blood vessel modified by the neurotrophic factors is transplanted in body, the scour and the pressure of hemodynamics are overcome in body, endothelial progenitor cells in circulation are captured initiatively, the endothelial progenitor cells are further induced to differentiate into endothelial cells in situ, and the progress and the quality of endothelialization of blood vessel graft are speeded. Meanwhile, the generation of blood capillaries is promoted and nurtured, the blood vessel implants are promoted to remodel in body, therefore, the effects of anti-thrombus formation and anti-intimal hyperplasia can be effectively achieved, and the patency rate after the small-caliber biotic artificial blood vessel is transplanted is increased. Active small-caliber tissue engineering blood vessels used for coronary arterie bypass grafting, hematodialysis and cerebrovascular replacement in clinic are built.

The invention discloses aspirin pulsed release pellets, its preparation and a preparation method thereof. The pellets comprise blank pellets, an aspirin-containing drug layer, an isolation layer, a regulation releasing layer and a protective layer. The regulation releasing layer contains polyprotic acid and/or its salt, anionic polymer salt, a plasticizer and an antiadherent. The anionic polymer salt is prepared by the following method: dissolving an enteric material, and using alkali to neutralize to a pH value greater than the enteric material dissolution pH value 0.1-3. The protective layer contains the enteric material, the plasticizer and the antiadherent. The enteric material is any one material selected from: an enteric material dissolved at pH value of 4.5-5.5 to prepare pellets I; an enteric material dissolved at pH value of 6.0-6.5 to prepare pellets II; or an enteric material dissolved at pH value of 7.0-8.0 to prepare pellets III. According to the preparation, local drug concentration will not be high, accumulation of the drug inside the body can be reduced, patient compliance can be improved, and stability inside the body can be raised. Therefore, bioavailability and the antithrombotic effect are raised.

The invention relates to the field of research into pharmaceutical chemistry, and particularly discloses a novel aromatic acid pro-drug with nitrogen monoxide donor, and a preparation method and application thereof in preventing and treating thrombotic diseases. In the invention, natural aromatic acid compounds with strong antithrombotic actions are structurally modified, and the carboxylic acid groups are incorporated with nitrogen monoxide donor to obtain the nitrogen monoxide donor type aromatic acid pro-drug with favorable liposolubility. The aromatic acid pro-drug with nitrogen monoxide donor has favorable solubility, can effectively permeate into the biomembrane lipid bimolecular layer, and can enhance the bioavailability after the human body takes the pro-drug. The pro-drug can be resolved into aromatic acid compounds and release nitrogen monoxide, and the aromatic acid compounds and nitrogen monoxide can cooperate to perform the pharmacological activities of resisting thrombi, resisting platelet aggregation and the like. The aromatic acid pro-drug with nitrogen monoxide donor can be used for preventing and treating thrombotic diseases and cerebral ischemia diseases.

The invention relates to anti-thrombogenic surfaces and a process for making said surfaces. The process is primarily used for the anti-thrombogenic coating of hydrophobic surfaces of medical products coming into direct contact with blood and coagulable blood products.

Disclosed is an antithrombotic neurovascular device useful for the treatment of brain aneurysms and/or acute ischemic stroke. The device comprises a mechanical structure, which may be a stent, stent-like structure, or flow diverter, and a drug-eluting coating. This device is designed for local delivery of antiplatelet medication to the site of device implantation in order to improve outcomes for the population of brain aneurysm and/or acute ischemic stroke patients currently being treated with stents, and for use with patients presenting with ruptured aneurysms, in whom systemic dual antiplatelet therapy is contraindicated. The coating comprises an antiplatelet drug, preferably, a GPIIb/IIIa receptor inhibitor, more preferably, abcixmab, and optionally comprises a polymeric binder that functions as a drug modulating polymer. Also disclosed are methods for producing the antithrombotic neurovascular device, and using the device for the treatment of brain aneurysms and/or acute ischemic stroke.